November 10-11 | In-Person & Digital (London) 

GLOBAL PHARMA AND BIOTECH SUMMIT

Rewriting the rules of growth, access and innovation

Use code EP10 to save 10% | Early Bird ends soon

New computing power, rising political scrutiny and a shifting global landscape are redrawing how pharma operates. The patent cliff is approaching, with drugs worth about $180 billion in annual revenue heading toward expiration, and the industry holds an estimated $1.3 trillion in dealmaking firepower to fill the gap. For those who move early, this is less a disruption story than an opportunity.

The Global Pharma and Biotech Summit, presented by the Financial Times in collaboration with Endpoints News, brings together the leaders defining that next phase. Chief executives, regulators and investors will tackle the stories dominating the news cycle: the dealmaking race to beat the patent cliff, pricing pressure spreading across the Atlantic and the regulatory shifts rewriting launch plans. It's two days of the reporting, access and insight this moment demands.

Keynote interviews

You'll hear directly from Shreeram Aradhye, president of development and chief medical officer of Novartis, in a keynote interview, and Lawrence Tallon, chief executive of the MHRA, on whether regulators can offer the predictability sponsors are losing elsewhere. Also joining:

• Kim Branson, chief AI officer at GSK, on whether the AI prize — leaner, more connected biopharma businesses — can be delivered in practice
• Richard Torbett, chief executive of the ABPI, on whether Europe can pay for innovation and compete globally for capital and talent
• Hong Chow, executive vice president of product and portfolio strategy at Novo Nordisk, on whether obesity drugs signal a new patient-to-consumer access model

Join us in London or online, and hear how the industry's leaders plan to turn this moment of disruption into the next phase of growth.

Use code EP10 to save 10% on your pass | Early Bird ends soon